NDATOPICALPATCH
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
ZTLIDO (lidocaine) by PharmaIN is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Approved for postherpetic neuralgia. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZTLIDO is a topical lidocaine 5% patch approved in February 2018 for the delivery of local anesthetic therapy. It is an amide local anesthetic that stabilizes neuronal membranes by inhibiting ionic fluxes required for impulse initiation and conduction, with onset of action occurring within 3-5 minutes of application. The product is indicated for topical anesthesia and is currently in peak lifecycle stage, representing an established therapeutic option in the local anesthetic patch market.
$0.1BPart D
5.0 years to LOEMechanism of Action
CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset of anesthesia: Lidocaine Ointment 5% effects local, topical anesthesia. The…
Worked on ZTLIDO at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.